Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.

BMJ (Clinical research ed.) - 10 Jan 1998

Sarasin F P, Bounameaux H

Abstract excerpt

OBJECTIVE: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended. DESIGN: A decision analysis Markov...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Factor V
Share to Heterozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Recurrence

Share to Risk Factors

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 9462312
DOI: 10.1136/bmj.316.7125.95
PMCID: PMC2665403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.PMID 9462312Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.Semantic proximity Read ↗

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?Semantic proximity Read ↗

Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.Semantic proximity Read ↗

Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group.Semantic proximity Read ↗

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.Semantic proximity Read ↗

The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.